Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

UNC Libraries(2020)10.17615/h6kv-p452Source: DataRank Database

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States is a research paper published in UNC Libraries (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.00)OA: greenTopics (52)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

François Guilhot ORCID,Martin Müller ORCID,Jiřı́ Mayer ORCID,Richard A. Larson ORCID,Susanne Saußele ORCID

Live enrichment

PubMed:30945415 OpenAlex:https://openalex.org/W4298243223

National Institutes of Health

Grant: 1F32HS023710-01

Using EHR Data to Dynamically Target Patients for Braden Scale Risk-Assessment

National Institutes of Health

Grant: 5UL1TR001111-05

North Carolina Translational & Clinical Sciences Institute (NC TraCS)

National Institutes of Health

Grant: 1K07CA138906-01A1

Oncology R&D: Expanding the Role of Economics to Aid Public Policy

FWCI

0.00

Citation Percentile

0.3%

greenLicense: CC BY NC

repositoryhttps://doi.org/10.17615/h6kv-p452

https://doi.org/10.1093/jnci/djw003

https://academic.oup.com/jnci/article-pdf/108/7/djw003/17315423/djw003.pdf

https://dx.doi.org/10.17615/h6kv-p452

https://pubmed.ncbi.nlm.nih.gov/26944912

Fields of Study

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research0302 clinical medicine03 medical and health sciences

Keywords

ImatinibMyeloid leukemiaTyrosine-kinase inhibitorTyrosine kinaseMedicineCancer researchPharmacologyInternal medicineReceptorCancerOncology & carcinogenesisMaleMedicin och hälsovetenskapCost-Benefit AnalysisPractice PatternsMedical and Health SciencesModelsAntineoplastic agentsChronicTreatment outcomePractice Patterns, Physicians'Middle agedLeukemiaMarkov chainsDrugsProtein-Tyrosine KinasesImatinib mesylatemyelogenousphysicians'FemaleQuality-Adjusted Life YearsModels, EconometricAdult330econometricProtein kinase inhibitors610Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Markov Chains; Middle Aged; Models, Econometric; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality-Adjusted Life Years; Survival Analysis; Treatment Outcome; United States; Drugs, Generic; Practice Patterns, Physicians'; Medicine (all); Oncology; Cancer ResearchGenericArticleLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrugs, GenericHumansAgedBCR-ABL positiveOncology and carcinogenesisSurvival analysisUnited States

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being